West Pharma director granted 791 RSUs

FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services director Robert F. Friel received a grant of 791 shares of common stock in the form of restricted stock units. The award carried a price of $0.00 per share as it is a compensation grant rather than an open-market purchase.

The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the Deferred Compensation Plan for Outside Directors. Following this award, Friel directly holds 5,512.97 shares of West Pharmaceutical Services common stock.

Insider Trade Summary

Grant/Award: 791 shares

Grant/Award 1 txn

Insider FRIEL ROBERT F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	791	$0.00	$0.00

Holdings After Transaction: Common Stock — 5,512.97 shares (Direct)

Footnotes (1)

1. F1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

Key Figures

RSUs granted: 791 shares Grant price: $0.00 per share Holdings after grant: 5,512.97 shares +1 more

4 metrics

RSUs granted 791 shares Restricted stock units awarded to director Robert F. Friel

Grant price $0.00 per share Compensation-related grant, not an open-market purchase

Holdings after grant 5,512.97 shares Total direct common stock holdings following the transaction

Transaction code A (Grant, award, or other acquisition) Form 4 non-derivative transaction classification

Key Terms

restricted stock units, Deferred Compensation Plan for Outside Directors, Common Stock, Form 4

4 terms

restricted stock units financial

"These shares of restricted stock units will vest in full on the date"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Deferred Compensation Plan for Outside Directors financial

"will be distributable under the terms of the Deferred Compensation Plan for Outside Directors"

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What did director Robert F. Friel receive in this West Pharmaceutical (WST) Form 4 filing?

Director Robert F. Friel received a grant of 791 restricted stock units of West Pharmaceutical common stock as compensation. The award price was $0.00 per share and increased his direct holdings to 5,512.97 shares after the transaction reported in this Form 4.

Is Robert F. Friel buying or being granted shares of West Pharmaceutical (WST)?

Robert F. Friel is being granted shares, not buying them on the market. The Form 4 shows a compensation-related acquisition of 791 restricted stock units at $0.00 per share, classified as a grant or award acquisition rather than an open-market purchase or sale.

When do Robert F. Friel’s 791 restricted stock units in West Pharmaceutical (WST) vest?

The 791 restricted stock units will vest in full on the date of the next annual shareholder meeting. At that time, they will be distributable under the company’s Deferred Compensation Plan for Outside Directors, according to the footnote disclosure in the Form 4 filing.

How many West Pharmaceutical (WST) shares does Robert F. Friel hold after this Form 4 transaction?

After the grant of 791 restricted stock units, Robert F. Friel directly holds 5,512.97 shares of West Pharmaceutical common stock. This total includes the newly awarded units and represents his direct ownership position following the reported transaction on the filing date.

What does the $0.00 per share price mean in this West Pharmaceutical (WST) Form 4?

The $0.00 per share price indicates the 791 shares were granted as compensation rather than purchased. They are restricted stock units awarded to director Robert F. Friel, vesting at the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRIEL ROBERT F

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		791(1)	A	$0	5,512.97	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

	/s/ Louis Lalli, as an agent for Robert F. Friel	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)